Correction to ASM Presentation Slide

Annual Shareholders’ Meeting 2021

Online Help

Your Board
Scott St John
Lewis Gradon
Sir Michael Daniell
Geraldine McBride
Neville MitchellDonal O’Dwyer
Pip Greenwood

Agenda
•Chair’s Address and Board Subcommittee Updates
•Managing Director and Chief Executive Officer’s Review
•Financial Statements
•Resolutions
•Voting
•General Questions

Operating
Revenue
↑
FY2021 Financial Highlights
Net Profit
After Tax
Dividend
$1.97B
$524.2M
56%
↑
38%
38.00cps
↑
82%

FY2021 Revenue by Product Group
Distributed & Other
<1%
OF OPERATING REVENUE
Homecare
24%
OF OPERATING REVENUE
Hospital
76%
OF OPERATING REVENUE

Overview
Overview
Overview
Overview
Hospital
F&P MR850
TM
Optiflow+

500.4
572.1
642.3
801.3
1498.1
FY17FY18FY19FY20FY21
Hospital Product Group
87%
NZ$
94%
Constant
Currency
↑
↑
FY21 Result
Revenue
FY21 Revenue Growth
$1.5B

Homecare
F&P MyAirvo2
TM
Optiflow+

381.5
398.1
421.4
4 57. 3
465.6
FY17FY18FY19FY20FY21
Homecare Product Group
2%
NZ$
4%
Constant
Currency
↑
↑
FY21 Result
Revenue
FY21 Revenue Growth
$466M

0%
5%
10%
15%
20%
25%
30%
35%
40%
201620172018201920202021
0%
10%
20%
30%
40%
50%
60%
70%
201620172018201920202021
Gross and Operating Margins
Gross Margin
Long Term Gross Margin Target – 65%
Operating (EBIT) Margin
Long Term Operating Margin Target –30%

Research and development -$136.7 million investment
See if we can
replace, we
used this one
last year

6,000+ people

Profit-sharing bonus -$29 million

Community
NZ $20MILLION
Fisher & Paykel Healthcare Foundation

FY22 Trading Update
First four months of FY22
•Revenue $583M, 2% below the prior comparable period in constant currency
•Hospital product group
−Revenue down 3% cc from prior comparable period
−13% decline in hardware sales from prior comparable period
−Hardware revenue remained elevated
−Consumables revenue +2% CC*
−New applications consumables +17% CC*
•Homecare product group
−Revenue +4% CC* from prior comparable period
−4% growth in OSA masks
*CC = Constant currency

Outlook for the remainder of FY22
For the remainder of the 2022 financial year*:
•No quantitative guidance provided given continuing uncertainties related to
COVID-19
•Hospital hardware revenue not expected to continue at elevated levels
•Hospital consumables sales will continue to be impacted by COVID-19
hospitalisation rates
•New OSA patient diagnosis rates expected to be at or above FY21 rates
•Freight costs remain elevated
•Continue to grow investment in R&D and SG&A
* Based on observations and expectations as at 18 August 2021

Financial Statements
•Opportunity for shareholders to ask
any questions specifically on the
financial statements, the auditor’s
report or the company’s 2021 annual
report.
•There will be an opportunity to ask
any general questions once all items
on the agenda have been considered.

Resolutions
1.Re-election of Scott St John as Director
2.Re-election of Sir Michael Daniellas Director
3.Auditor’s Remuneration
4.Issue of Performance Share Rights
5.Issue of Options

How to Vote Online
Voting boxQuestion box

Resolution 1: Re-election of Scott St John
That Scott St John, who retires by rotation
and, being eligible, offers himself for re-
election, be re-elected as a director of the
Company.
Click “Submit Vote” to lodge your vote.
Need help?
Call the Link Market Services helpline
0800 200 220

That Sir Michael Daniell, who retires by
rotation and, being eligible, offers himself
for re-election, be re-elected as a director
of the Company.
Resolution 2: Re-election of Sir Michael Daniell
Click “Submit Vote” to lodge your vote.
Need help?
Call the Link Market Services helpline
0800 200 220

Resolution 3: Auditor’s Remuneration
That the Directors be authorised to fix the
fees and expenses of PwC as the
Company’s auditor.
Click “Submit Vote” to lodge your vote.
Need help?
Call the Link Market Services helpline
0800 200 220

Resolution 4: Issue of Performance Share Rights
That approval be given for the issue of up
to 60,000performance share rights under
the Fisher & Paykel Healthcare
Performance Share Rights Plan to
Lewis Gradon, Managing Director and
Chief Executive Officer of the Company.
Click “Submit Vote” to lodge your vote.
Need help?
Call the Link Market Services helpline
0800 200 220

Resolution 5: Issue of Options
That approval be given for the issue of up
to 190,000 options under the
Fisher & Paykel Healthcare 2019 Share
Option Plan to Lewis Gradon, Managing
Director and Chief Executive Officer of the
Company.
Click “Submit Vote” to lodge your vote.
Need help?
Call the Link Market Services helpline
0800 200 220

Questions?

Overview
Overview
Overview
This concludes the 2021
Annual Shareholders’ Meeting.
Thank you for attending.